Full name
ONCONICK SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
uses securityreCAPTCHA
72.11.Z - Research and experimental development on biotechnology
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Assets | 1 | 1 | 1 | 0,2 |
Gross profit (loss) | 0 | -0 | -0 | -437,6 |
Net profit (loss) | 0 | -0 | -0 | -437,6 |
Cash | 0,2 | 0,2 | 0 | -99,8 |
Liabilities and provisions for liabilities | 0,8 | 0,8 | 0,8 | 0,3 |
Net income from sale | 0 | 0 | 0 | 0 |
Short time liabilities | 0 | 0 | 0 | 72,3 |
Equity capital | 0,2 | 0,2 | 0,2 | -0,3 |
Working assets | 1 | 1 | 1 | 0,2 |
Operating profit (EBIT) | 0 | -0 | -0 | -30 768,7 |
% | % | % | p.p. | |
Equity capital to total assets | 20 | 20,1 | 20 | -0,1 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 2 147 483 648 | 2 147 483 648 | 2 147 483 648 | 0 |
Current financial liquidity indicator | 1.2506823539733887 | 1.25100576877594 | 1.2496132850646973 | -0,1 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane